MXPA05010701A - Combinaciones sinergisticas de modulador o inmunosupresor de celula t de macrolido y un retinoide. - Google Patents

Combinaciones sinergisticas de modulador o inmunosupresor de celula t de macrolido y un retinoide.

Info

Publication number
MXPA05010701A
MXPA05010701A MXPA05010701A MXPA05010701A MXPA05010701A MX PA05010701 A MXPA05010701 A MX PA05010701A MX PA05010701 A MXPA05010701 A MX PA05010701A MX PA05010701 A MXPA05010701 A MX PA05010701A MX PA05010701 A MXPA05010701 A MX PA05010701A
Authority
MX
Mexico
Prior art keywords
macrolide
retinoid
synergistic combinations
inmunosuppressant
cell modulator
Prior art date
Application number
MXPA05010701A
Other languages
English (en)
Inventor
Gottfried Meingassner Josef
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05010701A publication Critical patent/MXPA05010701A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan combinaciones aditivas o sinergisticas de un inmunomodulador o inmunosupresor de celula T de macrolido tal como 33-epicloro-33-desoxiascomicina y un retinoide, tal como etretinato, isotretinoina o tazaroteno, opcionalmente con un agente farmaceuticamente activo adicional, en especial un antibacteriano, las cuales son adecuadas en particular para el tratamiento de enfermedades dermatologicas tales como eczema, dermatitis atopica, acne, psoriasis, envejecimiento de la piel, dano por el sol, eritema despues de desprendimiento, y marcas por estiramiento.
MXPA05010701A 2003-04-04 2004-04-02 Combinaciones sinergisticas de modulador o inmunosupresor de celula t de macrolido y un retinoide. MXPA05010701A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307864.9A GB0307864D0 (en) 2003-04-04 2003-04-04 Pharmaceutical composition
PCT/EP2004/003511 WO2004087118A2 (en) 2003-04-04 2004-04-02 Synergistic combinations of macrolide t-cell modulator or inmunosuppressant and a retinoid

Publications (1)

Publication Number Publication Date
MXPA05010701A true MXPA05010701A (es) 2005-12-12

Family

ID=9956227

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010701A MXPA05010701A (es) 2003-04-04 2004-04-02 Combinaciones sinergisticas de modulador o inmunosupresor de celula t de macrolido y un retinoide.

Country Status (13)

Country Link
US (1) US20060100187A1 (es)
EP (1) EP1638543A2 (es)
JP (1) JP2006522057A (es)
CN (1) CN100475199C (es)
AU (1) AU2004226819B2 (es)
BR (1) BRPI0408959A (es)
CA (1) CA2518245A1 (es)
GB (1) GB0307864D0 (es)
IS (1) IS8112A (es)
MX (1) MXPA05010701A (es)
NO (1) NO20055179L (es)
RS (1) RS20050660A (es)
WO (1) WO2004087118A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234250A1 (en) * 2005-04-15 2006-10-19 Powers Ralph W Iii Methods of screening and compositions for life span modulators
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
SG2014012173A (en) * 2009-05-20 2014-07-30 Ranbaxy Lab Ltd Topical retinoid solutions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003932D0 (en) * 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
US20040170635A1 (en) * 2001-02-01 2004-09-02 Vaishnaw Akshay K. Methods for treating or preventing skin disorders using cd2-binding agents
CA2442969A1 (en) * 2001-05-09 2002-11-14 Novartis Ag Methods for selective immunomodulation using pimecrolimus
CA2449671A1 (en) * 2001-06-06 2002-12-12 The Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
US7887842B2 (en) * 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject
PL378108A1 (pl) * 2003-02-14 2006-03-06 Combinatorx, Incorporated Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
GB0307862D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
BRPI0408959A (pt) 2006-04-04
AU2004226819B2 (en) 2008-02-28
US20060100187A1 (en) 2006-05-11
JP2006522057A (ja) 2006-09-28
WO2004087118A3 (en) 2005-04-07
IS8112A (is) 2005-11-01
RS20050660A (en) 2007-11-15
NO20055179L (no) 2006-01-04
NO20055179D0 (no) 2005-11-03
AU2004226819A1 (en) 2004-10-14
WO2004087118A2 (en) 2004-10-14
CN1764444A (zh) 2006-04-26
CN100475199C (zh) 2009-04-08
EP1638543A2 (en) 2006-03-29
GB0307864D0 (en) 2003-05-14
CA2518245A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
WO2008070116A3 (en) Topical compositions for treatment of skin conditions
CA2713555C (en) Topical compositions and methods for whitening skin
EP2144608A4 (en) SUN PROTECTION COMPOSITIONS AND METHODS
MX2007016462A (es) Composiciones topicas para tratar la piel.
WO2007092312A3 (en) Topical skin treating compositions
BRPI0411826A (pt) métodos de prevenir e reduzir a gravidade de estados associados ao estresse
WO2006120681A3 (en) Compositions and methods for skin care
WO2006083979A3 (en) Local treatment of neurofibromas
WO2011128700A3 (en) Apparatus for use as a motor or generator
TR201818983T4 (tr) İnflamatuvar Cilt Bozukluklarının Tedavisine Yönelik Olarak Sübstitüe Edilmiş Tetrasiklin Bileşikleri
EP1663959A4 (en) NEW AMIDINE COMPOUNDS FOR THE TREATMENT OF MICROBIAL INFECTIONS
WO2011117378A3 (en) Compositions comprising brimonidine for the treatment of erythema
IN2014DE01913A (es)
EP4153306A4 (en) COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL DISEASES
EP2059214A4 (en) MEDICATION FOR TREATING ACNE AND REVERSE SIGNS OF AGE AND SUN DAMAGE AND METHOD OF MANUFACTURE
EP4131561A4 (en) POWER SUPPLY DEVICE, VEHICLE INCLUDING SAME, AND ENERGY STORAGE DEVICE
WO2006102604A8 (en) Topical formulations of borinic acid antibodies and their methods of use
NO20055179L (no) Synergistiske kombinasjoner av makrolid T-celle modulator eller immunosupressivt stoff og et retionid
NO20055137L (no) Kombinasjon av et makrolid og et lokalbedovelsesmiddel for behandling av hudsykdommer
EP3381440A3 (en) Methods of improving the activity of retinoids
WO2006089070A3 (en) Acne gel
WO2006128169A3 (en) Inhibition of monocyte survival, differentiation, or proliferation
RS20050723A (en) Organic compounds
MXPA05010702A (es) Combinacion de un inmunomodulador de celula t de macrolido y un calciferol para el tratamiento de enfermedades de la piel o de enfermedad inflamatoria del intestino.
EP4131563A4 (en) POWER SOURCE DEVICE, AND VEHICLE AND ELECTRIC STORAGE DEVICE EACH EQUIPPED THEREWITH

Legal Events

Date Code Title Description
FA Abandonment or withdrawal